Intra-Cellular Therapies

Intra-Cellular Therapies is a pioneering biopharmaceutical company dedicated to developing innovative therapies for neuropsychiatric diseases. Established with a vision to transform the treatment landscape, the company focuses on addressing unmet medical needs in mental health.

With a robust pipeline of drug candidates, Intra-Cellular Therapies employs cutting-edge science and technology to create effective solutions for conditions such as schizophrenia and mood disorders. The company’s lead product, Caplyta (lumateperone), has shown promising results in clinical trials, demonstrating its potential to improve patient outcomes.

Intra-Cellular Therapies is committed to advancing research and development through collaboration with leading academic institutions and healthcare professionals. This collaborative approach ensures that the company remains at the forefront of scientific innovation.

The company’s mission is to enhance the quality of life for individuals suffering from debilitating mental health conditions. By prioritising patient-centric approaches, Intra-Cellular Therapies aims to deliver therapies that are not only effective but also well-tolerated.

In addition to its focus on drug development, Intra-Cellular Therapies actively engages in educational initiatives to raise awareness about mental health issues. The company believes that education is key to reducing stigma and improving access to care.

As a socially responsible organisation, Intra-Cellular Therapies adheres to the highest ethical standards in its operations. The company is dedicated to transparency and accountability, ensuring that stakeholders are informed about its progress and challenges.

Intra-Cellular Therapies is headquartered in the UK, where it fosters a culture of innovation and excellence. The company’s team comprises experienced professionals who are passionate about making a difference in the lives of patients.

Looking ahead, Intra-Cellular Therapies is poised for growth as it continues to expand its portfolio and explore new therapeutic areas. The company remains steadfast in its commitment to improving mental health care globally.